reference/4468891

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/4468891

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study
endingPage	790
issn	1432-0843 0344-5704
issueIdentifier	4
pageRange	781-790
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	781
bibliographicCitation	Rolland D, Ribrag V, Haioun C, Ghesquieres H, Jardin F, Bouabdallah R, Franchi P, Briere J, De Kerviler E, Chassagne-Clement C, Raponi M, Houlgatte R, Jais JP, Thieblemont C. Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. Cancer Chemother Pharmacol. 2010 Mar;65(4):781–90. doi: 10.1007/s00280-009-1185-4. PMID: 19960345.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7801-6534 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0095-5379 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf4f1c9ce9777c377b8cbfc26055ebe9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b0000407ac9e4b61dfd53da842d41eb0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f9eef2ff3a4d1dec94abd869296d571 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1531acdf17ca06170fa44dee98bec07b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8aa54507c0036cb02fc1851e0cfdece4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e622b347e109d715c37b8f16a31806f8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_73caa340f28acce302151a81cf57f15f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9ff5c6f90dd0d818391928ad5f3c120b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39c39bcb8e103770115ba0089892c5f2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe3ce7cd928a8172740b5f29714c3e17 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ca3b04318c2d430166cbd7be8ab3538c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47573050146a218946dc8a4e29021994 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4c58228c12bafb7e774745f36dc1b62d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7c447e69235ce601587ed5c7609e0ac0
date	2009-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/19960345 https://doi.org/10.1007/s00280-009-1185-4
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664 https://portal.issn.org/resource/ISSN/1432-0843 https://portal.issn.org/resource/ISSN/0344-5704
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://scigraph.springernature.com/ https://www.crossref.org/
title	Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d’Etude des Lymphomes de l’Adulte trial
discusses	http://id.nlm.nih.gov/mesh/M0507519 http://id.nlm.nih.gov/mesh/M0328201 http://id.nlm.nih.gov/mesh/M0355462 http://id.nlm.nih.gov/mesh/M0226821 http://id.nlm.nih.gov/mesh/M0015042 http://id.nlm.nih.gov/mesh/M0023650 http://id.nlm.nih.gov/mesh/M0403572 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0006678 http://id.nlm.nih.gov/mesh/M0470710 http://id.nlm.nih.gov/mesh/M0017909 http://id.nlm.nih.gov/mesh/M0024173
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID159324 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9856 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_15af60ccc94fe9313e50881eedd81cff http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_3d05f6753309a9ac1617e6c8aedc488f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10603 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_678856b20c71c7ec6b56a4d4433b61e2 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d6ff811e2f4338cfb3363095186a8098 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_2.5.1.29

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID54840 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11214 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136112251 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID10125

Total number of triples: 62.